TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: TACE (transarterial chemoembolization) combined with targeted/immunotherapy.
- Who it may be relevant to
- Registry conditions: Hepatocellular Carcinoma (HCC). Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Study of the Safety, Clinical Efficacy and Prognostic Factors of TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for Hepatocellular Carcinoma
Overview
The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma (HCC) require further in-depth study. This research aims to evaluate the safety, clinical efficacy and prognostic factors of TACE and/or HAIC combined with targeted immunotherapy for hepatocellular carcinoma. We are going to compare and analyze local tumor response, survival outcomes, prognostic factors and adverse events. Tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version. Adverse events were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. This study intends to include the targeted and immunotherapy applied, mainly including: lenvatinib, sorafenib, apatinib, bevacizumab, etc.; pembrolizumab, carfilzomib, sintilimab and teprotumumab, etc.
Interventions
- Procedure TACE (transarterial chemoembolization) combined with targeted/immunotherapy
transarterial chemoembolization
Primary outcome measures
- Overall survival(OS) [Time frame: 1-, 2-, 3-, and 5-year]
Secondary outcome measures (1)
- Progression-free survival (PFS) [Time frame: 1-, 2-, and 3-year]
Eligibility criteria
Inclusion criteria
- aged 18-80 years
- Eastern Cooperative Oncology Group (ECOG) performance status score < 2
- maximum tumor diameter ≥ 7 cm
- IVC/RA TT diagnosed by contrast-enhanced CT / MRI before study treatment
- unresectable HCC (uHCC) confirmed by a specialized multidisciplinary team
- liver function of Child-Pugh class A or B
Exclusion criteria
- with other malignancies
- prior anti-tumor therapy
- history of drug allergy
- autoimmune diseases
- digestive hemorrhage of any grade
- insufficient renal, bone marrow, or coagulation function
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Jiayan Ni — Guangzhou
Identifiers
NCT: NCT07658833 · SYSKY-2025-1049-01